Page last updated: 2024-12-10

allithiamine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth

Description

allithiamine: RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID12358373
SCHEMBL ID19533172
MeSH IDM0059952

Synonyms (7)

Synonym
554-44-9
allithiamine
thiamin-allyl-disulfid
n-[(4-amino-2-methyl-5-pyrimidinyl)methyl]-n-[4-hydroxy-1-methyl-2-(2-propenyldithio)-1-butenyl]formamide, 9ci
SCHEMBL19533172
n-[(4-amino-2-methylpyrimidin-5-yl)methyl]-n-[5-hydroxy-3-(prop-2-enyldisulfanyl)pent-2-en-2-yl]formamide
thiaminetetrahydrofurfuryldisulfide

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
"Lipid-soluble thiamine precursors have a much higher bioavailability than genuine thiamine and therefore are more suitable for therapeutic purposes."( Benfotiamine, a synthetic S-acyl thiamine derivative, has different mechanisms of action and a different pharmacological profile than lipid-soluble thiamine disulfide derivatives.
Bettendorff, L; Evrard, B; Gangolf, M; Piette, M; Plumier, JC; Seyen, S; Volvert, ML, 2008
)
0.35
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (16)

TimeframeStudies, This Drug (%)All Drugs %
pre-199010 (62.50)18.7374
1990's2 (12.50)18.2507
2000's2 (12.50)29.6817
2010's0 (0.00)24.3611
2020's2 (12.50)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials2 (12.50%)5.53%
Reviews2 (12.50%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (75.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]